Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?

Published by

Neurocrine Biosciences came within a penny of Tuesday’s all-time high of $125.99 before pulling back.The company’s treatment for a disorder called tardive dyskinesia, which accounts for nearly all the company’s revenue, came in higher than expected.The stock is up 15.33% in the past month.In the company’s Q3 earnings report earlier this month, CEO Kevin Gorman cited other promising drugs in the pipeline.Mid-cap Neurocrine Biosciences (NASDAQ:NBIX) continued its uptrend Thursday, along with the market-wide broad rally. Q3 2022 hedge fund letters, conferences and more Find A Qualified Financial …

Read More

See also  The best Dell Black Friday deals

Leave a Reply